ChinaPeptides: difference between revisions
Diff·revision 16 → 17·20:19, 19 Apr 2025
Difference between revision 16 and revision 17 of ChinaPeptides. 4 lines changed; the page grew by 549 bytes.
| Revision 16 — 08:29, 5 Apr 2025 API_Aurora (talk) fix the anchor on an internal link 7,367 bytes +80 | Revision 17 — 20:19, 19 Apr 2025 MicrodoseMagnus (talk) rm the discount code added by an anonymous editor 7,916 bytes +549 | ||
|---|---|---|---|
| 53 | Submitted reports on QYB material to July 2026 divide roughly evenly between stock and custom items. For custom items, several purchasers ran independent mass confirmation and reported agreement with the supplier's own figure.{{r|reports}} | 53 | Submitted reports on QYB material to July 2026 divide roughly evenly between stock and custom items. For custom items, several purchasers ran independent mass confirmation and reported agreement with the supplier's own figure.{{r|reports}} |
| 54 | 54 | ||
| + | 55 | That is a stronger form of verification than a purity comparison, because it addresses identity rather than relative composition. It remains a statement about individual samples: none was drawn under a documented [[Chain of custody|chain of custody]], and identity confirmation on one vial says nothing about the next.{{r|reports,iso17025}} | |
| + | 56 | ||
| 55 | == References == | 57 | == References == |
| 56 | {{reflist}} | 58 | {{reflist}} |
| ⋮ | ⋮ | ||
| 60 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 62 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 61 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 63 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 64 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 62 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 65 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 63 | 66 | ||
| ⋮ | ⋮ | ||
| 68 | * [[Peptide content]] | 71 | * [[Peptide content]] |
| 69 | * [[Research use only]] | 72 | * [[Research use only]] |
| + | 73 | * [[Peptide supply chain]] | |
| 70 | 74 | ||
| 71 | {{DEFAULTSORT:ChinaPeptides}} | 75 | {{DEFAULTSORT:ChinaPeptides}} |